Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology
March 01, 2018 08:36 ET
|
Helsinn Healthcare S.A.
Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology Eleven finalists have been selected from a strong roster of talent to compete at the...
Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding Patent Covering Aloxi® in the US Market
February 28, 2018 15:14 ET
|
Helsinn Healthcare S.A.
Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding Patent Covering Aloxi® in the US Market Lugano, Switzerland, and Woodcliff Lake, N.J., February 28, 2018 - In...
Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU)
February 27, 2018 12:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU) Lugano, Switzerland February 27, 2018 - Helsinn, a Swiss pharmaceutical group...
Helsinn Healthcare S.A.: Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement
January 30, 2018 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement Investigating the role of pharmacological inhibitors in kidney cancer Lugano, Switzerland, January 30, 2018 -...
Helsinn: US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid
January 17, 2018 13:41 ET
|
Helsinn Healthcare S.A.
US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid Lugano,...
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)
January 11, 2018 09:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML) Lugano, Switzerland...
Helsinn Healthcare S.A.: A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award
January 09, 2018 08:31 ET
|
Helsinn Healthcare S.A.
A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award The Award recognizes Patient...
Helsinn to honor Anna Braglia Endowed Young Investigator Award recipient at Helsinn reception during JP Morgan Healthcare Conference 2018
January 08, 2018 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn to honor Anna Braglia Endowed Young Investigator Award recipient at Helsinn reception during JP Morgan Healthcare Conference 2018 Dr. Sarah A. Buckley to be recognized as the...
Helsinn Group supports Satellite Symposium at 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting
December 05, 2017 03:01 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports Satellite Symposium at 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting Lugano, Switzerland, December 5, 2017 - Helsinn, a Swiss pharmaceutical group...
Helsinn Investment Fund.: A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award
November 15, 2017 07:15 ET
|
Helsinn Healthcare S.A.
A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award The Award recognizes Patient...